OncoGenex names new CFO
This article was originally published in Scrip
Executive Summary
OncoGenex Pharmaceuticals, a biopharmaceutical company developing therapies that address treatment resistance in cancer patients, has named John A Bencich vice-president and chief financial officer. Mr Bencich joins the Bothell, Washington based firm from Integrated Diagnostics, where he was also CFO. He will report directly to OncoGenex president and CEO Scott Cormack.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.